In contrast, leukemia cells with Ppm1d loss displayed an increased sensitivity to agents commonly used in the treatment of myeloid neoplasia including daunorubicin, cytarabine, decitabine, and azacitidine (Figure 4C). This evidence concerns the gene PPM1D and leukemia.